MYC network mutations in high-risk chronic lymphocytic leukaemia

Hematological Oncology

Volumn 32, Issue 3, 2014, Pages 155-157

  Monti, Sara ^a   Deambrogi, Clara ^a   Rinaldi, Andrea ^b   Bertoni, Francesco ^b,c   Gaidano, Gianluca ^a   Rossi, Davide ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; MYC PROTEIN;

5' UNTRANSLATED REGION; BURKITT LYMPHOMA; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DNA SEQUENCE; GENE MUTATION; GENE REGULATORY NETWORK; HIGH RISK PATIENT; HUMAN; LETTER; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TREATMENT PLANNING; GENE EXPRESSION REGULATION; GENETICS; MUTATION;

GENE EXPRESSION REGULATION, LEUKEMIC; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84921724235     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2117     Document Type: Letter

References (12)

1. Zhang W, Kater AP, Widhopf GF 2nd, et al. B-cell activating factor and v-MYC myelocytomatosis viral oncogene homolog (c-MYC) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010; 107: 18956-18960.
2. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011; 117: 3391-3401.
3. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-MYC in Burkitt lymphoma. Science 1987; 238: 1272-1275.
4. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
5. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012; 120: 4783-4794.
6. De Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 1087-1090.
7. Dühren-von Minden M, Übelhart R, Schneider D, et al. Chronic lymphocytic leukaemias driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309-312.
8. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-1325.
9. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316-1320.
10. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
11. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.
12. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutationof multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-346.